# EDGAR Filing Document

**Accession Number:** 0001308547
**File Stem:** 0001171843-23-000636
**Filing Date:** 2023-2
**Character Count:** 34718
**Document Hash:** 65d04b5f130211ffba3fa8581070684f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-23-000636.hdr.sgml**: 20230202

**ACCESSION NUMBER**: 0001171843-23-000636

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230202

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230202

**DATE AS OF CHANGE**: 20230202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dolby Laboratories, Inc.
- **CENTRAL INDEX KEY:** 0001308547
- **STANDARD INDUSTRIAL CLASSIFICATION:** PATENT OWNERS & LESSORS [6794]
- **IRS NUMBER:** 900199783
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0927

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32431
- **FILM NUMBER:** 23581072

**BUSINESS ADDRESS:**
- **STREET 1:** 1275 MARKET STREET
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94103
- **BUSINESS PHONE:** 415 558 0200

**MAIL ADDRESS:**
- **STREET 1:** 1275 MARKET STREET
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94103

?xml version="1.0" encoding="utf-8"? Form 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

### Washington, D.C. 20549
_________________

### FORM 8-K
_________________

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): February 2, 2023
_______________________________

#### Dolby Laboratories, Inc.
(Exact name of registrant as specified in its charter)

_______________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-32431** | **90-0199783** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

#### 1275 Market Street

#### San Francisco, California 94103-1410
(Address of Principal Executive Offices) (Zip Code)

(415) 558-0200

(Registrant's telephone number, including area code)

#### Not Applicable
(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| Title of each class | Name of each exchange on which registered |
| **Class A common stock, $0.001 par value** **DLB** | **The New York Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Section 2 - Financial Information** 

**ITEM 2.02. Results of Operations and Financial Condition.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following information is intended to be furnished under Item 2.02 of Form 8-K, "Results of Operations and Financial Condition." This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February 2, 2023, Dolby Laboratories, Inc. (the "Company") issued a press release announcing its financial results for its fiscal quarter ended December 30, 2022. The full text of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

**Section 8 – Other Events**

**ITEM 8.01. Other Events.**

*Declaration of Dividend*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February 2, 2023, the Company announced a cash dividend of $0.27 per share of Class A and Class B Common Stock, payable on February 22, 2023 to stockholders of record as of the close of business on February 14, 2023.

*Disclosure Channels to Disseminate Information*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company disseminates information to the public about the Company, its products, services and other matters through various channels, including the Company's website (www.dolby.com), investor relations website (http://investor.dolby.com), SEC filings, press releases, public conference calls and webcasts, in order to achieve broad, non-exclusionary distribution of information to the public. The Company encourages investors and others to review the information it makes public through these channels, as such information could be deemed to be material information.

**Section 9 - Financial Statements and Exhibits**

**ITEM 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.** 

---

| | |
|:---|:---|
| **<u>Exhibit<br> No.</u>**  | **<u>Description</u>** |
| [99.1](exh_991.htm) | [Press Release of Dolby Laboratories, Inc. dated February 2, 2023](exh_991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Dolby Laboratories, Inc.** | **Dolby Laboratories, Inc.** |
| Date: February 2, 2023 | By: | <u>/s/ Robert Park&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  |  | Robert Park |
|  |  | Senior Vice President and Chief Financial Officer (Principal Financial Officer) |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**Dolby Laboratories Reports First Quarter 2023 Financial Results**

SAN FRANCISCO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the first quarter of fiscal 2023.

"We are bringing an increasing number of Dolby experiences to more people around the world and demand for immersive experiences continues to be strong," said Kevin Yeaman, President and CEO, Dolby Laboratories. "I'm excited about our momentum with Dolby Vision and Dolby Atmos in movies, television, music, live sports and more."

**First Quarter Fiscal 2023 Financial Highlights**

* Total revenue was $334.9 million, compared to $351.6 million for the first quarter of fiscal 2022.

* GAAP net income was $79.4 million, or $0.82 per diluted share, compared to GAAP net income of $80.0 million, or $0.77 per diluted
share, for the first quarter of fiscal 2022. On a non-GAAP basis, first quarter net income was $107.4 million, or $1.11 per diluted share,
compared to $104.5 million, or $1.01 per diluted share, for the first quarter of fiscal 2022.

* Cash flows from operations were $56.4 million, compared to $31.7 million for the first quarter of fiscal 2022.

* We repurchased 0.7 million shares of our common stock and ended the quarter with about $311 million of stock repurchase authorization
available going forward.

A complete listing of Dolby's non-GAAP measures are described and reconciled to the corresponding GAAP measures at the end of this release.

**Recent Business Highlights**

* Vivo launched its flagship phone with both Dolby Vision capture and playback.

* OPPO announced their OnePlus 11 phone will include Dolby Atmos and Dolby Vision playback.

* TCL announced that Dolby Vision and Dolby Atmos will be included on all new 4K TVs in the US.

**Dividend**

Today, Dolby announced a cash dividend of $0.27 per share of Class A and Class B common stock, payable on February 22, 2023, to stockholders of record as of the close of business on February 14, 2023.

**Financial Outlook**

Dolby's financial outlook relies on estimates of royalty-based revenue that take into consideration the macroeconomic effect of certain events, including COVID-19, supply chain constraints, and consumer demand for electronic products. In addition, our actual results could differ materially from the estimates we are providing below due in part to the increased uncertainty resulting from these items as well as the geopolitical instability and continuing concerns around inflation and rising interest rates. The uncertainty resulting from these factors has greatly reduced our visibility into our future outlook. To the extent possible, the estimates we are providing for future periods reflect certain assumptions about the potential impact of certain of these items, based upon a consideration of currently available external and internal data and information. These assumptions are subject to risks and uncertainties. For more information, see "Forward-Looking Statements" in this press release for a description of certain risks that we face, and the section captioned "Risk Factors" in our Quarterly Report on Form 10-Q for the first quarter of fiscal 2023, to be filed on or around the date hereof.

Dolby is providing the following high-level estimates for the full year of fiscal 2023:

* Total revenue is expected to grow low single digits year-over-year.

* GAAP operating expenses are expected to decline roughly 2% year-over-year. Non-GAAP operating expenses are expected to grow roughly
2% year-over-year.

* We expect operating margins on a GAAP basis to be roughly 19% and on a non-GAAP basis to be roughly 30%.

Dolby is providing the following estimates for its second quarter of fiscal 2023:

* Total revenue is estimated to range from $340 million to $370 million.

* Operating expenses are anticipated to range from $227 million to $237 million on a GAAP basis and from $193 million to $203 million
on a non-GAAP basis.

* Effective tax rate is anticipated to range from 22% to 24% on a GAAP basis and 19% to 21% on a non-GAAP basis.

* Diluted earnings per share is anticipated to range from $0.58 to $0.73 on a GAAP basis and from $0.90 to $1.05 on a non-GAAP basis.

**Conference Call Information**

Members of Dolby management will lead a conference call open to all interested parties to discuss first quarter fiscal 2023 financial results for Dolby Laboratories at 2:00 p.m. PT (5:00 p.m. ET) on Thursday, February 2, 2023. Access to the teleconference will be available at <u>http://investor.dolby.com</u> or by dialing 1-844-200-6205 (or dialing 1-929-526-1599 for international callers) and entering confirmation code 719331.

A replay of the call will be available from 5:00 p.m. PT (8:00 p.m. ET) on Thursday, February 2, 2023, until 11:00 p.m. PT on Thursday, February 9, 2023 (2:00 a.m. ET on Friday, February 10, 2023), by dialing 1-866-813-9403 (international callers can access the replay by dialing +44-204-525-0658) and entering the confirmation code 561757. An archived version of the teleconference will also be available on the Dolby website, <u>http://investor.dolby.com</u>.

**Non-GAAP Financial Information**

To supplement Dolby's financial statements presented on a GAAP basis, Dolby management uses, and Dolby provides to investors, certain non-GAAP financial measures as an additional tool to evaluate Dolby's operating results in a manner that focuses on what Dolby's management believes to be its ongoing business operations and performance. Specifically, we exclude the following as adjustments from one or more of our non-GAAP financial measures:

*Stock-based compensation expense*: Stock-based compensation, unlike cash-based compensation, utilizes subjective assumptions in the methodologies used to value the various stock-based award types that we grant. These assumptions may differ from those used by other companies. To facilitate more meaningful comparisons between our underlying operating results and those of other companies, we exclude stock-based compensation expense.

*Amortization of acquisition-related intangibles*: We amortize intangible assets acquired in connection with acquisitions. These intangible assets consist of patents and technology, customer relationships, and other intangibles. We record amortization charges relating to these intangible assets in our GAAP financial statements, and we view these charges as items arising from pre-acquisition activities that are determined by the timing and valuation of our acquisitions. As these amortization charges do not directly correlate to our operations during any particular period, we exclude these charges to facilitate an evaluation of our current operating performance and comparisons to our past operating results.

*Restructuring charges/(credits)*: Restructuring charges/(credits) are costs associated with restructuring plans and primarily relate to costs associated with exit or disposal activities, employee severance benefits, and asset impairments. We exclude restructuring costs, including any adjustments to charges recorded in prior periods (which may be credits), as we believe that these costs are not representative of our normal operating activities and therefore, excluding these amounts enables a more effective comparison to our past operating performance.

*Income tax adjustments*: We believe that excluding the income tax effect of the aforementioned non-GAAP adjustments provides a more accurate view of our underlying operating results to management and investors.

Using the aforementioned adjustments, Dolby provides various non-GAAP financial measures including, but not limited to: non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating margin, and non-GAAP effective tax rate. Dolby's management believes it is useful for itself and investors to review both GAAP and non-GAAP measures to assess the performance of Dolby's business, including as a means to evaluate period-to-period comparisons. Dolby's management does not itself, nor does it suggest that investors should, consider non-GAAP financial measures in isolation from, superior to, or as a substitute for, financial information prepared in accordance with GAAP. Whenever Dolby uses non-GAAP financial measures, it provides a reconciliation of the non-GAAP financial measures to the most closely applicable GAAP financial measures. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as detailed above and below. Investors are also encouraged to review Dolby's GAAP financial statements as reported in its US Securities and Exchange Commission (SEC) filings. A reconciliation between GAAP and non-GAAP financial measures is provided at the end of this press release and on the Dolby investor relations website, <u>http://investor.dolby.com</u>.

**Forward-Looking Statements**

Certain statements in this press release, including, but not limited to, statements relating to Dolby's financial results for the first quarter of fiscal 2023, expected financial results for the second quarter of fiscal 2023 and full year fiscal 2023, our ability to expand existing business, navigate challenging periods, pursue our long-term growth opportunities, and advance our other long-term objectives, and future dividend payments are "forward-looking statements" that inherently involve substantial risks and uncertainties. These forward-looking statements are based on management's current expectations, and as a result of certain risks and uncertainties, actual results may differ materially from those provided. The following important factors, without limitation, could cause actual results to differ materially from those in the forward-looking statements: the potential impacts of COVID-19 and economic conditions on Dolby's business operations, financial results, and financial position (including the impact to Dolby partners and disruption of the supply chain and delays in shipments of consumer products; consumer demand for products that incorporate Dolby technologies; delays in the development and release of new products or services that contain Dolby technologies; delays in royalty reporting or delinquent payment by partners or licensees; lengthening sales cycles; the impact to the overall cinema market, including closures or limitations of cinema capacity and resulting adverse impact to Dolby's revenue recognized on box-office sales and demand for cinema products and services; temporary Dolby office closures and other actions to protect Dolby's workforce; and macroeconomic conditions that affect discretionary spending and access to products that contain Dolby technologies); risks associated with geopolitical issues, such as the conflict between Russia and Ukraine; risks associated with trends in the markets in which Dolby operates, including the broadcast, mobile, consumer electronics, PC, and other markets; the loss of, or reduction in sales by, a key customer, partner, or licensee; pricing pressures; risks relating to changing trends in the way that content is distributed and consumed; risks relating to conducting business internationally, including trade restrictions and changes in diplomatic or trade relationships; risks relating to the expiration of patents; the timing of Dolby's receipt of royalty reports and payments from its licensees, including recoveries; changes in tax regulations; timing of revenue recognition under licensing agreements and other contractual arrangements; Dolby's ability to develop, maintain, and strengthen relationships with industry participants; Dolby's ability to develop and deliver innovative products and technologies in response to new and growing markets; competitive risks; risks associated with conducting business in China and other countries that have historically limited recognition and enforcement of intellectual property and contractual rights; risks associated with the health of the motion picture industry generally; Dolby's ability to increase its revenue streams and to expand its business generally, and to continue to expand its business beyond its current technology offerings; risks associated with acquiring and successfully integrating businesses or technologies; and other risks detailed in Dolby's SEC filings and reports, including the risks identified under the section captioned "Risk Factors" in our Quarterly Report on Form 10-Q filed on or around the date hereof. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements. Forward-looking statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Dolby disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

**About Dolby Laboratories**

Dolby Laboratories (NYSE: DLB) is based in San Francisco, California with offices around the globe. From movies and TV shows, to apps, music, sports and gaming, Dolby transforms the science of sight and sound into spectacular experiences for billions of people worldwide. We partner with artists, storytellers, developers, and businesses to revolutionize entertainment and communications with Dolby Atmos, Dolby Vision, Dolby Cinema, and Dolby.io.

Dolby, Dolby Atmos, Dolby Vision, Dolby Cinema, Dolby.io, and the double-D symbol are among the registered and unregistered trademarks of Dolby Laboratories in the United States and/or other countries. Other trademarks remain the property of their respective owners.

**DOLBY LABORATORIES, INC.**

**INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(*in thousands, except per share amounts; unaudited*)

---

| | | |
|:---|:---|:---|
|  | **Fiscal Quarter Ended** | **Fiscal Quarter Ended** |
|  | **December 30,**<br>**2022** | **December 31,**<br>**2021** |
| **Revenue:** | | |
| &nbsp;&nbsp;&nbsp;&nbsp;Licensing | $308011 | $332284 |
| &nbsp;&nbsp;&nbsp;&nbsp;Products and services | 26910 | 19349 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 334921 | 351633 |
| **Cost of revenue:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of licensing | 13359 | 14935 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of products and services | 21091 | 17774 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total cost of revenue | 34450 | 32709 |
| **Gross margin** | 300471 | 318924 |
| **Operating expenses:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 64450 | 68824 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 82205 | 97170 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 59972 | 62444 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring credits | (244) | (95) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 206383 | 228343 |
| **Operating income** | 94088 | 90581 |
| **Other income/(expense):** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 4878 | 716 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (81) | (84) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income, net | 1097 | 229 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other income | 5894 | 861 |
| Income before income taxes | 99982 | 91442 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | (20534) | (11432) |
| Net income including controlling interest | 79448 | 80010 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: net (income)/loss attributable to controlling interest | (73) | 4 |
| **Net income attributable to Dolby Laboratories, Inc.** | $**79375** | $**80014** |
| Net income per share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.83 | $0.79 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.82 | $0.77 |
| Weighted-average shares outstanding: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 95905 | 101230 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 97047 | 103801 |

---

**DOLBY LABORATORIES, INC.**

**INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS**

(*in thousands; unaudited*)

---

| | | |
|:---|:---|:---|
|  | **December 30,**<br>**2022** | **September 30,**<br>**2022** |
| **ASSETS** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $626158 | $620127 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | 5319 | 8244 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 132875 | 189213 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 289597 | 243593 |
| &nbsp;&nbsp;&nbsp;&nbsp;Contract assets, net | 215923 | 176093 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 26111 | 23549 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 53432 | 50075 |
| Total current assets | 1349415 | 1310894 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term investments | 124024 | 102514 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant, and equipment, net | 512168 | 513481 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 43355 | 46530 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill and intangible assets, net | 475297 | 477412 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred taxes | 192184 | 183568 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-current assets | 52080 | 55149 |
| **Total assets** | $**2748523** | $**2689548** |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $17361 | $14171 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 230346 | 230237 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 7183 | 1265 |
| &nbsp;&nbsp;&nbsp;&nbsp;Contract liabilities | 22356 | 18588 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 13201 | 13257 |
| Total current liabilities | 290447 | 277518 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-current contract liabilities | 22734 | 23203 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-current operating lease liabilities | 34221 | 37685 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-current liabilities | 108596 | 100122 |
| Total liabilities | 455998 | 438528 |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Class A common stock | 54 | 53 |
| &nbsp;&nbsp;&nbsp;&nbsp;Class B common stock | 41 | 41 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 2319358 | 2297730 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (31875) | (51641) |
| Total stockholders' equity – Dolby Laboratories, Inc. | 2287578 | 2246183 |
| &nbsp;&nbsp;&nbsp;&nbsp;Controlling interest | 4947 | 4837 |
| Total stockholders' equity | 2292525 | 2251020 |
| **Total liabilities and stockholders' equity** | $**2748523** | $**2689548** |

---

**DOLBY LABORATORIES, INC.**

**INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(*in thousands; unaudited*)

---

| | | |
|:---|:---|:---|
|  | **Fiscal Quarter Ended** | **Fiscal Quarter Ended** |
|  | **December 30,**<br>**2022** | **December 31,**<br>**2021** |
| **Operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income including controlling interest | $79448 | $80010 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 19155 | 23477 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 31240 | 32656 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of operating lease right-of-use assets | 3207 | 3944 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of premium on investments | 81 | 311 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for/(benefit from) credit losses | (1030) | 1559 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (8255) | (9004) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-cash items affecting net income | (3467) | (358) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | (45153) | (9965) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract assets, net | (39843) | (44428) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (501) | (1819) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 1690 | (77) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 2168 | (7082) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | 5765 | (34034) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes, net | 15292 | 1439 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract liabilities | 3277 | 3350 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (5430) | (4038) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-current liabilities | (1249) | (4281) |
| Net cash provided by operating activities | 56395 | 31660 |
| **Investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of marketable securities | (72790) | (108147) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sales of marketable securities | 51782 | 2001 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from maturities of marketable securities | 56525 | 10913 |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant, and equipment | (7217) | (14452) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of intangible assets |  | (11426) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of other investments |  | (5000) |
| Net cash provided by/(used in) investing activities | 28300 | (126111) |
| **Financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock | 10954 | 21372 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common stock | (49412) | (35573) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of cash dividend | (25869) | (25283) |
| &nbsp;&nbsp;&nbsp;&nbsp;Distribution to controlling interest | (266) | (1435) |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares repurchased for tax withholdings on vesting of restricted stock | (25000) | (31920) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of deferred consideration for prior business combinations | (500) |  |
| Net cash used in financing activities | (90093) | (72839) |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash | 8504 | (1310) |
| Net increase/(decrease) in cash, cash equivalents, and restricted cash | 3106 | (168600) |
| Cash, cash equivalents, and restricted cash at beginning of period | 628371 | 1233032 |
| Cash, cash equivalents, and restricted cash at end of period | $**631477** | $**1064432** |

---

---

| | | | |
|:---|:---|:---|:---|
| **GAAP to Non-GAAP Reconciliations** | **GAAP to Non-GAAP Reconciliations** | **GAAP to Non-GAAP Reconciliations** | **GAAP to Non-GAAP Reconciliations** |
| *(in millions, except per share data; unaudited)* | *(in millions, except per share data; unaudited)* | *(in millions, except per share data; unaudited)* | *(in millions, except per share data; unaudited)* |
| The following tables present Dolby's GAAP financial measures reconciled to the non-GAAP financial measures included in this release for the first quarter of fiscal 2023 and fiscal 2022: | The following tables present Dolby's GAAP financial measures reconciled to the non-GAAP financial measures included in this release for the first quarter of fiscal 2023 and fiscal 2022: | The following tables present Dolby's GAAP financial measures reconciled to the non-GAAP financial measures included in this release for the first quarter of fiscal 2023 and fiscal 2022: | The following tables present Dolby's GAAP financial measures reconciled to the non-GAAP financial measures included in this release for the first quarter of fiscal 2023 and fiscal 2022: |
| **Net income:** |  | **Fiscal Quarter Ended** | **Fiscal Quarter Ended** |
|  |  | **December 30,**<br>**2022** | **December 31,**<br>**2021** |
| GAAP net income |  | $79.4 | $80.0 |
| Stock-based compensation <sup>(1)</sup> |  | 31.2 | 32.7 |
| Amortization of acquisition-related intangibles <sup>(2)</sup> |  | 1.3 | 2.8 |
| Restructuring credits |  | (0.2) | (0.1) |
| Income tax adjustments |  | (4.3) | (10.9) |
| Non-GAAP net income |  | $107.4 | $104.5 |
| (1) Stock-based compensation included in above line items: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of products and services |  | $0.5 | $0.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development |  | 10.7 | 10.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing |  | 10.7 | 12.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative |  | 9.3 | 9.7 |
| (2) Amortization of acquisition-related intangibles included in above line items: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of licensing |  | $— | $0.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of products and services |  | 0.9 | 0.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development |  | 0.1 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing |  | 0.8 | 1.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative |  | (0.5) |  |
| **Diluted earnings per share:** |  | **Fiscal Quarter Ended** | **Fiscal Quarter Ended** |
|  |  | **December 30,**<br>**2022** | **December 31,**<br>**2021** |
| GAAP diluted earnings per share |  | $0.82 | $0.77 |
| Stock-based compensation |  | 0.32 | 0.31 |
| Amortization of acquisition-related intangibles |  | 0.01 | 0.03 |
| Income tax adjustments |  | (0.04) | (0.10) |
| Non-GAAP diluted earnings per share |  | $1.11 | $1.01 |
| Weighted-average shares outstanding - diluted |  | 97 | 104 |
| The following tables present a reconciliation between GAAP and non-GAAP versions of the estimated financial amounts for the second quarter of fiscal 2023 and full year fiscal 2023 included in this release: | The following tables present a reconciliation between GAAP and non-GAAP versions of the estimated financial amounts for the second quarter of fiscal 2023 and full year fiscal 2023 included in this release: | The following tables present a reconciliation between GAAP and non-GAAP versions of the estimated financial amounts for the second quarter of fiscal 2023 and full year fiscal 2023 included in this release: | The following tables present a reconciliation between GAAP and non-GAAP versions of the estimated financial amounts for the second quarter of fiscal 2023 and full year fiscal 2023 included in this release: |
| **Operating expenses:** | **Q2 2023** | **Fiscal 2023** | **Fiscal 2023** |
| GAAP operating expenses (low - high end of range) | $227 - $237 | (2%) +/- year-over-year | (2%) +/- year-over-year |
| Stock-based compensation | (33) | (124 | (124) |
| Amortization of acquisition-related intangibles | (1) | (4 | (4) |
| Non-GAAP operating expenses (low - high end of range) | $193 - $203 | +2% +/- year-over-year | +2% +/- year-over-year |
| **Operating margin:** |  | **Fiscal 2023** | **Fiscal 2023** |
| GAAP operating margin |  | 19% +/- | 19% +/- |
| Stock-based compensation |  | 10 | 10% |
| Amortization of acquisition-related intangibles |  | 1 | 1% |
| Non-GAAP operating margin |  | 30% +/- | 30% +/- |
| **Effective tax rate:** |  |  | **Q2 2023** |
| GAAP effective tax rate (low - high end of range) |  |  | 22% - 24% |
| Stock-based compensation (low - high end of range) |  |  | (2%) - (1%) |
| Amortization of acquisition-related intangibles (low - high end of range) |  |  | (1%) - 0% |
| Other (low - high end of range) |  |  | (1%) - 0% |
| Non-GAAP effective tax rate (low - high end of range) |  |  | 19% - 21% |
| **Diluted earnings per share:** |  | **Q2 2023** | **Q2 2023** |
|  |  | **Low** | **High** |
| GAAP diluted earnings per share |  | $0.58 | $0.73 |
| Stock-based compensation |  | 0.35 | 0.35 |
| Amortization of acquisition-related intangibles |  | 0.02 | 0.02 |
| Income tax adjustments |  | (0.05) | (0.05) |
| Non-GAAP diluted earnings per share |  | $0.90 | $1.05 |
| Weighted-average shares outstanding - diluted |  | 97 | 97 |

---

**Investor Contact:**

Maggie O'Donnell

Dolby Laboratories

914-267-7390

investor@dolby.com

**Media Contact:**

Karen Hartquist

Dolby Laboratories, Inc.

415-505-8357

karen.hartquist@dolby.com